Synergistic combinations of known therapeutic agents offer a new route for the development of novel therapies. Such therapies are potentially more active and provide safer solutions for patients suffering from a variety of diseases.

Dermipsor’s drugs are combination therapeutics that target two or more physiological pathways that are involved in the disease.  The administration of a combination therapy creates a synergistic effect that is more effective against the disease than each of the separate ingredients acting on their own. .

The combination approach offers a fast route for drug development since the safety profile of each ingredient is well characterized, and the individual components have already been approved by the regulatory authorities.